Get the Stockscreener App
113.95
1.37%
1.67
Glaukos Corporation stock is traded at $113.95, with a volume of 262.99K.
It is up +1.37% in the last 24 hours and up +4.90% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$112.28
Open:
$112.63
24h Volume:
262.99K
Relative Volume:
0.25
Market Cap:
$6.55B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-38.50
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
+0.81%
1M Performance:
+4.90%
6M Performance:
+12.19%
1Y Performance:
-27.32%
1-Day Range:
$112.55
$114.56
1-Week Range:
$109.07
$114.56
52-Week Range:
$73.16
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
114.01 | 6.45B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
127.06 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.64 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.09 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.56 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.52 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Will Glaukos Corporation stock gain from government policies2026 world cup usa national team round of 32 defensive leaders low block defense expert forecast guide - ulpravda.ru
Glaukos Corporation's (NYSE:GKOS) Shift From Loss To Profit - simplywall.st
Glaukos approved for $14M Alabama tax credit - Lagniappe Daily
Block Trades: How geopolitical risks impact Glaukos Corporation 6GJ stockWeekly Profit Report & Capital Efficient Trade Techniques - moha.gov.vn
Allspring Global Investments Holdings LLC Sells 13,317 Shares of Glaukos Corporation $GKOS - MarketBeat
Glaukos Corporation (NYSE:GKOS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Glaukos Corporation (NYSE:GKOS): Are Analysts Optimistic? - Yahoo Finance
Glaukos price target raised to $145 from $115 at Stephens - Yahoo Finance
Glaukos (NYSE:GKOS) Given Buy Rating at BTIG Research - MarketBeat
Glaukos stock maintains Buy rating at BTIG on Epioxa launch potential - Investing.com
Glaukos stock maintains Buy rating at BTIG on Epioxa launch potential By Investing.com - Investing.com Nigeria
Avoiding Lag: Real-Time Signals in (GKOS) Movement - Stock Traders Daily
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - Finviz
Harbor Capital Advisors Inc. Decreases Stake in Glaukos Corporation $GKOS - MarketBeat
Glaukos price target raised to $125 from $113 at Citi - MSN
Glaukos Corp (NYSE:GKOS) Shares Rise After Quarterly Results - Kalkine Media
Glaukos Corporation $GKOS Shares Purchased by Voya Investment Management LLC - MarketBeat
UBS Maintains Glaukos (GKOS) Buy Recommendation - Nasdaq
J.P. Morgan Healthcare Conference - marketscreener.com
Glaukos Corporation $GKOS Shares Purchased by Riverbridge Partners LLC - MarketBeat
Glaukos Corporation $GKOS Shares Sold by Texas Permanent School Fund Corp - MarketBeat
Why Glaukos Corporation (6GJ) stock is listed among top recommendations2025 Fundamental Recap & Target Return Focused Picks - Улправда
EBIT per share of Glaukos Corp – DUS:6GJ - TradingView — Track All Markets
Assenagon Asset Management S.A. Has $12.85 Million Stock Holdings in Glaukos Corporation $GKOS - MarketBeat
Technical Reactions to GKOS Trends in Macro Strategies - Stock Traders Daily
What valuation multiples suggest for Glaukos Corporation stockJuly 2025 Spike Watch & Daily Stock Trend Reports - Улправда
How Glaukos Corporation stock benefits from strong dollar2025 Growth vs Value & Weekly High Conviction Ideas - DonanımHaber
Can Glaukos Corporation stock resist market sell offsJuly 2025 Fed Impact & Free Reliable Trade Execution Plans - DonanımHaber
How Glaukos Corporation stock compares to industry benchmarksJuly 2025 Spike Watch & Daily Volume Surge Signals - DonanımHaber
Is Glaukos Corporation stock positioned for digital transformationJuly 2025 Intraday Action & Stock Portfolio Risk Control - ulpravda.ru
Will Glaukos Corporation stock outperform growth indexesJuly 2025 Trade Ideas & Weekly High Return Forecasts - Улправда
Market Overview: Is Glaukos Corporation stock positioned for digital transformationPortfolio Risk Report & Low Risk Profit Maximizing Plans - Улправда
February 2026 Options Now Available For Glaukos (GKOS) - Nasdaq
Truist Financial Issues Positive Forecast for Glaukos (NYSE:GKOS) Stock Price - MarketBeat
Truist Securities Adjusts Price Target on Glaukos Corp to $145 From $120, Maintains Buy Rating - marketscreener.com
Piper Sandler reiterates Overweight rating on Glaukos stock as 2026 top pick By Investing.com - Investing.com South Africa
Piper Sandler reiterates Overweight rating on Glaukos stock as 2026 top pick - Investing.com Nigeria
Glaukos breaks ground on high-tech facility in Alabama, eyes 150 jobs - Alabama Weather Network
Glaukos Announces Participation in J.P. Morgan Healthcare Conference - BioSpace
Revenue per share of Glaukos Corp – GETTEX:6GJ - TradingView — Track All Markets
Glaukos (NYSE: GKOS) joins 44th J.P. Morgan Healthcare Conf Jan. 13 - Stock Titan
Glaukos (GKOS): Reassessing Valuation After Citigroup’s Rating Update and iDose TR Commercial Launch - simplywall.st
Glaukos (NYSE: GKOS) CEO reports new performance-based RSUs and options - Stock Titan
Glaukos (GKOS) President & COO earns 7,316 stock options after goals met - Stock Titan
Glaukos Corporation (NYSE: GKOS) discloses CFO earning 3,660 stock options - Stock Titan
Glaukos Corp (GKOS) CDO Earns 2,054 Performance-Based Shares in 2025 - Stock Titan
Stifel reiterates Buy rating on Glaukos stock, maintains $115 price target - Investing.com Nigeria
Glaukos price target raised to $125 from $117 at Needham - MSN
Glaukos Corporation $GKOS Shares Purchased by Holocene Advisors LP - MarketBeat
Gilder Gagnon Howe & Co. LLC Decreases Position in Glaukos Corporation $GKOS - MarketBeat
Eventide Asset Management LLC Sells 70,181 Shares of Glaukos Corporation $GKOS - MarketBeat
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):